Investment Thesis
Mira is a pre-revenue stage pharmaceutical company with minimal commercial traction ($44.9K revenue, declining -40.3% YoY) and significant operating cash burn ($1.2M annually), resulting in a net margin of -2561%. While the strong balance sheet ($9.3M equity, zero debt) and improving loss trend (+67.4% YoY) provide financial runway, the absence of any meaningful business fundamentals or demonstrated commercialization capability makes the company unsuitable for fundamental-based investment at this stage.
Strengths
- Exceptionally strong liquidity position (82.16x current ratio) with minimal financial distress risk
- Zero long-term debt with $4.8M cash reserves representing 51% of total assets
- Improving loss trajectory with net income losses declining 67.4% year-over-year
Risks
- Virtually non-existent revenue base ($44.9K) with accelerating -40.3% YoY revenue decline
- Substantial ongoing operating cash burn ($1.2M annually) against minimal revenue generation
- Typical biotech execution risk with unproven pipeline and unclear path to commercialization; cash runway approximately 4 years at current burn rate
Key Metrics to Watch
- Revenue growth rate reversal from -40.3% decline
- Operating cash burn trajectory and monthly burn rate
- Clinical pipeline development milestones and regulatory progress
Financial Metrics
Revenue
44.9K
Net Income
-1.2M
EPS (Diluted)
$-0.03
Free Cash Flow
-1.2M
Total Assets
9.5M
Cash
4.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
-2,561.1%
ROE
-12.3%
ROA
-12.2%
FCF Margin
-2,674.9%
Balance Sheet & Liquidity
Current Ratio
82.16x
Quick Ratio
82.16x
Debt/Equity
0.00x
Debt/Assets
1.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:48:24.633723 |
Data as of: 2026-03-31 |
Powered by Claude AI